Founder & CEO

The science was proven by the founder. The product will be built by the company.

SilkMatrix is founded by the scientist who demonstrated that silk-fibroin cryogels can work for bone fixation. The deep domain expertise, the regulatory know-how, and the vision sit in one person — and the venture builds its own clinical-grade product and IP from there.

Why This Founder

The rare founder who is the scientist and the regulatory expert — with feasibility already proven in his own hands.

Arvind Rathore is a biomedical scientist with 10+ years of experience spanning silk biomaterials, cell & molecular biology, and medical-device regulation. His graduate research at IIT Kanpur on silk-based biomaterials produced a high-concentration silk-fibroin cryogel that demonstrated the feasibility of using silk for load-bearing bone-fixation constructs — the scientific foundation this venture is built on.

He then deepened the implant story through a Marie Skłodowska-Curie Fellowship (Horizon 2020) at INSERM U1026 BioTis, Bordeaux — bench-level ISO 10993 biological evaluation of implantable devices: cytotoxicity, foreign-body response, sterilization effects, and biomaterial–cell interactions. Today he runs MedDev Advisory, preparing biocompatibility documentation for EU MDR, FDA 510(k), and India / CDSCO submissions.

“Years ago I proved, in the lab, that a silk-fibroin cryogel could meet bone-fixation requirements. Since then I’ve spent my career learning exactly how to prove an implant is safe and get it through regulators. SilkMatrix is where I bring those two halves of my work together — to build a modern, clinical-grade product.”
Areas of Expertise Silk Fibroin Processing Cryogel & Scaffold Fabrication Cell & Molecular Biology ISO 10993 Biological Evaluation (BEP · BER · TRA) Biocompatibility & Cytotoxicity Mechanical Characterization (SEM, compression) EU MDR / FDA 510(k) / CDSCO Preclinical / Rodent Models
The Scientific Foundation

The feasibility was proven by the founder — in his own hands.

This is not a founder who simply found a market. It is a scientist who personally demonstrated that the core science works, then spent a decade mastering how to turn science into an approved device — the strongest possible founder–venture fit.

Graduate research · IIT Kanpur

Designed and tested silk-fibroin cryogel scaffolds with orthopaedic potential — engineered to mimic native bone — establishing the founder’s hands-on command of the material.

Bone-like strength

Produced cryogel constructs reaching compressive strength comparable to human bone with porosity like cancellous bone — verified by SEM & mechanical testing.

Proven feasibility

Demonstrated that silk-based cryogels are a credible route to bioresorbable orthopaedic constructs — tunable mechanics and confirmed cytocompatibility — the green light for this venture.

All intellectual property will be created for, and owned entirely by, SilkMatrix — built on a decade of the founder’s domain expertise.
Capability ↔ Requirement

Every hard requirement maps to the founder’s real experience.

Investors fund execution. Here is how the founder’s background directly de-risks each critical milestone.

What the company must doWhy it’s hardFounder’s proven capability
Make a silk bone-fixation materialNiche material + mechanical know-howAlready proved it’s possible — built a silk-fibroin cryogel with bone-like strength with his own hands
Pass ISO 10993 biological evaluationTop reason implant files failISO 10993 consultant by profession; bench cytotoxicity at INSERM
Engineer & characterise scaffoldsRequires biomaterials + cell biologyMTech silk biomaterials; SEM, mechanical testing, cytocompatibility; 10+ yrs cell & molecular biology
Run preclinical studiesAnimal models, surgery, ethicsCertified in rodent surgery & animal experimentation (3R); in-vivo implant work at INSERM
Clear EU MDR / FDA / CDSCOMulti-jurisdiction regulatory mazesActive practice across EU MDR, FDA 510(k) & India / CDSCO
Build & protect new, owned IPDefensible, unencumbered patents are criticalFree-to-operate starting point (no prior institutional patent); trained in patent search, analysis & strategy (EPO / IPR)
Track Record

Career & education.

2023 – Present

Founder & ISO 10993 Consultant — MedDev Advisory

Biocompatibility documentation (BEP, BER, TRA) for EU MDR, CE Mark & FDA 510(k). Scientific guidance to MedTech startups on biological evaluation.

2020 – 2023 · Marie Curie ESR

Scientist — INSERM U1026 BioTis, Bordeaux

Marie Skłodowska-Curie Fellow (Horizon 2020 ImplantSens). Implantable-biosensor biocompatibility & ISO 10993 in-vitro / in-vivo evaluation. Visiting work at CNRS (France), Ruhr University Bochum (Germany) & AptuSens (Sweden).

2015 – 2016 · IIT Kanpur

Research Assistant — Silk Cryogels for Orthopaedic Implants

Engineered silk-fibroin cryogel pins/screws with bone-like compressive strength; SEM & cytocompatibility.

2013 – 2015 · Education

MTech — IIT Kanpur

Thesis: Development of Silk-based Biomaterials for Tissue Engineering — including a high-concentration silk cryogel for bone-fracture fixation. AICTE Fellowship.

2017 – 2018 · IIT Ropar

Research Scholar — Cell & Molecular Biology

Adipocyte–macrophage crosstalk in inflammation & insulin resistance — deep cell-biology training.

2010 – 2012 · Education

MSc — Hydrogels for Bioengineering

Synthesised & characterised stimuli-responsive hydrogels; biocompatibility & biodegradability studies.

Honours, Awards & Output

Verifiable, competitive, and published.

Marie Curie Fellow

EU Horizon 2020 — one of Europe’s most competitive research fellowships.

GATE AIR-76

99.41 percentile nationally; AICTE / MHRD Fellowship for MTech.

Peer-reviewed author

Publications incl. Bioelectrochemistry (Elsevier, 2025) & Adv. Sensor Research (Wiley, 2024).

International network

Research across France, Germany & Sweden; conferences incl. ESB & ECI.

View publications on ResearchGate ↗
Selected Publications

Primary, verifiable scientific output.

2025

Demurtas D, Alvarez-Malmagro J, Rathore A, et al. Development of Flexible Nanoporous Gold Electrodes for the Detection of Glucose. Bioelectrochemistry, Vol. 165, 108949. Elsevier.

2024

Rathore A, Bennett R, Gounel S, et al. Effects of Sterilization on a Cellobiose Dehydrogenase-based glucose biosensor. Advanced Sensor Research, 2400056. Wiley.

2019

Rathore A K. Silk as a Biopolymer for Tissue Engineering Applications. Int. Journal of Innovative Research in Science, Engineering & Technology, Vol. 8(6).

2018

Banerjee D, … Rathore A K., et al. Inflammation-induced mTORC2-Akt-mTORC1 signaling promotes macrophage foam cell formation. Biochimie, Vol. 151. Elsevier.

2015

Rathore A K., Kumar A. Silk Fibroin-based Cryogel Scaffolds for Tissue Engineering Applications. Int. Conference Bio-Tech, IIT Kanpur.

Full publication & conference list available on the founder’s ResearchGate and LinkedIn profiles.

Honest & De-risked

Aware of the gaps — and building to fill them.

The founder covers the company’s scientific and regulatory core. SilkMatrix is structured to surround that with the remaining expertise a device company needs.

  • ✓Silk science & biocompatibilityFounder-led — the company’s core internal strength.
  • ✓Regulatory (ISO 10993 / MDR / FDA / CDSCO)Founder-led, professionally.
  • ✓Orthopaedic clinical inputSurgeon advisors engaged for fixation design.
  • ✓Manufacturing, QMS & commercialPartners & advisors being assembled.
See team & advisors →
Microscope view of a silk-fibroin scaffold showing a honeycomb of interconnected pores
Talk to the Founder

Back the scientist who proved the science — and can ship the product.

For investor and advisory conversations, reach out directly — or request the confidential brief.

Investor BriefContact the Founder